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ABCA1Poly(ADP-ribose) polymerase-2 (PARP-2) is acknowledged as a DNA repair enzyme. However, recent investiga-
tions have attributed unique roles to PARP-2 inmetabolic regulation in the liver.We assessed changes in hepatic
lipid homeostasis upon the deletion of PARP-2 and found that cholesterol levels were higher in PARP-2−/−mice
as compared to wild-type littermates. To uncover the molecular background, we analyzed changes in steady-
state mRNA levels upon the knockdown of PARP-2 in HepG2 cells and in murine liver that revealed higher
expression of sterol-regulatory element binding protein (SREBP)-1 dependent genes. We demonstrated that
PARP-2 is a suppressor of the SREBP1 promoter, and the suppression of the SREBP1 gene depends on the
enzymatic activation of PARP-2. Consequently, the knockdown of PARP-2 enhances SREBP1 expression that in
turn induces the genes driven by SREBP1 culminating in higher hepatic cholesterol content. We did not detect
hypercholesterolemia, higher fecal cholesterol content or increase in serum LDL, although serum HDL levels
decreased in the PARP-2−/−mice. In cells and mice where PARP-2 was deleted we observed decreased ABCA1
mRNA and protein expression that is probably linked to lower HDL levels. In our current study we show that
PARP-2 impacts on hepatic and systemic cholesterol homeostasis. Furthermore, the depletion of PARP-2 leads
to lower HDL levels which represent a risk factor to cardiovascular diseases.
© 2013 Elsevier B.V. All rights reserved.ding cassette transporter A1;
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Poly(ADP-ribose) polymerase (PARP)-2 (also known as ARTD2)
belongs to the PARP superfamily [1]. PARP-2 binds to DNA nicks and
abnormal DNA structures through the SAP motif on its N-terminus [2]
that activates PARP-2. Active PARP-2 cleaves NAD+ to form poly(ADP-
ribose) polymers attached to itself and to other acceptor proteins
[1,3], however to date the proteins poly(ADP-ribosyl)ated by PARP-2
are poorly mapped.
PARP-2 participates in a plethora of processes such as DNA repair
and genome surveillance, spermatogenesis, T cell maturation, inﬂam-
mation and mediates oxidative injury [4]. PARP-2 was recently identi-
ﬁed as a metabolic transcriptional regulator by inﬂuencing the activity
of thyroid transcription factor 1, peroxisome proliferator activated
receptor-γ (PPARG), pancreatic and duodenal homeobox 1 (pdx-1)
and SIRT1 [5–7]. Through these transcription factors PARP-2 regulates
metabolism in white adipose tissue (WAT), pancreatic beta cells,
skeletal muscle and liver [5,6]. Partial deletion of PARP-2 decreases
PPARG and pdx-1 activity, which hampers WAT and beta cell function
[5,6]. In skeletal muscle and liver the knockdown of PARP-2 induced
SIRT1 expression and activity that consequently resulted in the
deacetylation of downstream SIRT1 targets such as FOXO1 (forkhead
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(PGC-1α). Deacetylation of these cofactors by SIRT1 leads to increased
expression of genes involved in mitochondrial biogenesis leading to
enhanced fatty acid oxidation [5].
Although several PARP isoforms were shown to inﬂuence meta-
bolic processes, only PARP-2 was identiﬁed to regulate hepatic me-
tabolism [8] (hepatic fatty acid accumulation upon the deletion of
PARP-1 does not seem to stem from changes in hepatic metabolism
[8–10]). The unique hepatic action of PARP-2 prompted us to assess
in detail the role of PARP-2 in the regulation of lipid metabolism in
the liver.2. Materials and methods
2.1. Chemicals
All chemicals, includingUPF1069,were from Sigma-Aldrich (St. Louis,
USA) unless stated otherwise.2.2. Cell culture
HepG2 human hepatocarcinoma cells were obtained from ATCC and
were cultured in DMEM (1 g/L glucose, 10% FCS and for the selection
of transduced cells 0.25 μg/mL puromycin). PARP-2 silencing was
performed using the same lentiviral constructs as in [5]. For silencing
we employed constructs harboring a PARP-2 speciﬁc shPARP-2
small hairpin sequence or an unspeciﬁc scPARP-2 (scrambled) shRNA.
The constructs were delivered to HepG2 cells via lentiviral particles
(Sigma) using 40 MOI lentiviruses, and then puromycin-resistant
cells were selected giving rise to PARP-2 silenced shPARP-2 HepG2
and control scPARP-2 HepG2 cell.2.3. Animal studies
All animal experiments were carried out conforming to the national,
EU and PHS ethical guidelines and were authorized by the Institutional
Animal Care and Use Committee at the University of Debrecen (7/2010
DEMÁB). Homozygousmale PARP-2−/− and littermate PARP-2+/+mice
[11] derived from heterozygous crossings were kept in a 12/12 h dark–
light cycle with ad libitum access to water and food (10 kcal% of fat,
SAFE, Augy, France). Animals were sacriﬁced after 6 h of fasting (always
in the same time, 12:00 p.m.), and tissues were collected and processed
as speciﬁed.2.4. Biochemical assays
Cholesterol and phospholipids in HepG2 cells, in liver and in
fecal samples were determined by biochemical techniques after Floch
extraction using kits from Diagnosztikum (Budapest, Hungary) and
WAKO (Richmond, VA, USA). Serum cholesterol, LDL and HDL were
determined using commercial kits from Diagnosztikum.2.5. SDS-PAGE, Western blotting
Protein extraction, SDS-PAGE and Western blotting were performed
as in [5]. Blots were probed with the following antibodies: SREBP1,
SREBP2 (both 1:1000, Santa Cruz, Santa Cruz, CA, USA), HMGCS1,
HMGCR, ABCA1 (1:1000, Abcam, Cambridge, UK), anti-poly(ADP-ribose)
(mouse monoclonal antibody, 10H, Axxora, Lausen, Switzerland), actin
(1:1000, Sigma) and PARP-2 (1:1000, Alexis, Lausen, Switzerland). Blots
were quantiﬁed using the Image J software, then densitometry data
were analyzed by statistical methods.2.6. Cell fractionation
scPARP-2 and shPARP-2 HepG2 cells were pelleted bymild centrifu-
gation at 4 °C at 1500 rpm for 3 min. The pellets were homogenized
with ﬁve volumes of homogenization buffer (0.5 M sucrose, 20 mM
HEPES pH 7.5, 1 mM EDTA, 1 mM EGTA and protease inhibitors) on
ice and then Nonidet P-40 was added to a ﬁnal concentration of 0.5%.
The lysates were kept on ice and vortexed several times. Lysates were
centrifuged at 8000 ×g at 4 °C for 15 min. The supernatants were
considered as cytosolic fractions. The pellets containing the nuclei
were resuspended in four volumes of a buffer containing 0.35 M
sucrose, 10 mM HEPES pH 7.9, 3.3 mMMgCl2, 10 mM KCl, 0.5 mM DTT
and protease inhibitors. The suspensions were then sonicated on ice for
30 s, and the sonicated suspensions were used as nuclear fractions.
2.7. Immunocytochemistry and confocal microscopy
Confocal microscopic imaging was carried out at the Molecular Cell
Analysis Core Facility at the University of Debrecen. For immunodetection
of SREBP1 and SREBP2 5 × 105 cells were seeded in eachwell of u-Slide 8
well chamber (ibidi, Munich, Germany). Cells were stained with an anti-
SREBP1 or an anti-SREBP2 antibody (both in 1:50, Santa Cruz, Santa Cruz,
CA, USA) antibody using the protocol described in [12]. Streptavidin-
Alexa 488 conjugated secondary antibody was used at a dilution of
1:300 (60 min at room temperature). Nuclei were counterstained with
propidium iodide (1 μg/ml). An Olympus FV1000 confocal laser scanning
microscope equippedwith an UPLSAPO 60× oil immersion objective (NA
1.35) was used to collect stacks of 512 × 512 pixel optical slices with a z-
step size of 500 nm. Alexa 488 (marking SREBP1 and SREBP2) and PI (la-
beling the nucleus) were excited at 488 and 543 nm, and detected be-
tween 500–300 and 555–655 nm, respectively. The pinhole was set to
120 μm. The ratio of SREBP1 and SREBP2 concentrationswithin the nucle-
us and the cytoplasm was estimated from ﬂuorescence intensities in
these compartments. For analysis the brightest optical slice was selected
from each cell. Separate regions of interest containing the nucleus and cy-
toplasmic areas were drawn by using the FluoView 3.0 software, and
mean ﬂuorescence intensities per pixel within the regions of interest
were calculated. Background ﬂuorescence was determined from cells in-
cubated with the secondary antibody alone. The ratio of background-
corrected intensities of nuclear to cytoplasmic intensities was calculated
for ~10 cells in each sample. This ratio is proportional to the ratio of anti-
body (i.e. SREBP1/SREBP2) concentrations within these cellular compart-
ments. Ratios measured for control and knockdown samples were
compared by Student's t-tests.
2.8. DNA constructs and luciferase activity measurement
pGL2-SREBP1c-2600luc SREBP1 promoter was described previously
[13], the luciferase reporter plasmid harboring the promoter of ABCA1
(pLightSwitch_Prom-ABCA1) was from Switchgear Genomics (Menlo
Park, CA, USA). PARP-2 mediated transactivation was determined in
reporter assays as in [5]. Brieﬂy, 1 × 105 scPARP-2 and shPARP-2 HepG2
cells were seeded in 6 well plates. The following day cells were
transfected with 2.5 μg pGL2-SREBP1c-2600luc/pLightSwitch_Prom-
ABCA1 and 0.5 μg β-galactosidase expression plasmid (pCMV-βgal)
using JetPEI (PolyPlus, Strasbourg, France). After 24 h cells were washed
with PBS, scraped and stored at −80 °C. Luciferase assay was carried
out by standard procedures. Luciferase activity was normalized to
β-galactosidase activity.
2.9. Microarray experiments and validation
Total RNAwas extracted fromHepG2 cells using the RNeasyMini Kit
(Qiagen). RNA integrity was checked on Agilent Bioanalyser 2100
(Agilent Technologies), RNA samples with N9.0 RIN value were used in
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Fig. 1. Deletion of PARP-2 leads to higher hepatic cholesterol and lower serum HDL levels in vivo. (A–E) Liver cholesterol (A) and phospholipid (B) content, fecal (C) and serum
(D) cholesterol, serum LDL and HDL (E) levelswere determined in PARP-2+/+ and PARP-2−/−mice (n = 7/6, age 6 months). * and ** indicate statistically signiﬁcant differences between
PARP-2+/+ and PARP-2−/−mice at p b 0.05 and p b 0.01, respectively. Error is given as SEM.
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RNA concentration.
Global expression pattern was analyzed on Affymetrix GeneChip
Human Gene 1.0 ST arrays. Ambion WT Expression Kit (Life Technolo-
gies, Hungary) and GeneChip WT Terminal Labelling and Control Kit
(Affymetrix) were used for amplifying and labeling 250 ng of total RNA
samples. Samples were hybridized at 45 °C for 16 h and then standard
washing protocol was performed using Affymetrix GeneChip Fluidics
Station 450, the arrays were scanned on GeneChip Scanner 7G
(Affymetrix). RNA labeling and hybridization were processed by UD-
GenoMed Medical Genomic Technologies Ltd. (Debrecen, Hungary).
Upon analysis low values (b500) were omitted as no, or low expres-
sions of genes and the rest were normalized. The respective values for
each gene were compared (shPARP-2 HepG2 vs. scPARP-2 HepG2 cells)
using anunpaired t-test after Bonferroni correction andp b 0.05was con-
sidered as signiﬁcant. Dysregulated geneswere analyzed using the BINGO
software of Cytoscape in order to classify the genes into biochemical path-
ways and functions. Hits were veriﬁed in RT-qPCR reactions. Raw and
processed data is uploaded to NCBI GEO (accession No. GSE43981).2.10. RT-qPCR and chromatin immunoprecipitation
cDNA synthesis and RT-qPCR, were performed as described in [14],
and primers are summarized in Supplementary Table 1. Chromatin
immunoprecipitation was performed as in [14], and primers are
summarized in Supplementary Table 2.Fig. 2. PARP-2 knockdown leads to higher expression of SREBP1-dependent genes. (A–B) PARP
blots in HepG2 cells treated with PARP-2 speciﬁc (shPARP-2), or a non-speciﬁc control shRNA
content of scPARP-2 and shPARP-2 HepG2 cells (n = 3/3) was extracted by Floch extraction
(D) Gene expression was analyzed in scPARP-2 and shPARP-2 HepG2 cells (n = 3/3) using mic
as heatmaps. All abbreviations are in the text. (E) mRNA levels of HMGCS1 and HMGCR (two SR
mice (n = 7/6, age 6 months). * and *** indicate statistically signiﬁcant differences between
p b 0.05 and p b 0.001, respectively. In panel E error is given as SEM.2.11. Statistical analysis
Statistical analysis of the microarray experiments was described
above. In other cases, statistical signiﬁcance was determined using
Student's t-test. Error bars represent SD unless stated otherwise.3. Results
3.1. Depletion of PARP-2 induces hepatic cholesterol levels and lowers
serum HDL
Ourprevious study already showed that the deletion of PARP-2 leads
to lower triglyceride levels in the liver due to higher mitochondrial
activation through SIRT1 [5]. As an extension to that observation we
analyzed the cholesterol and phospholipid levels in the livers of PARP-
2+/+ and PARP-2−/−mice (Fig. 1A–B). Hepatic cholesterol levels were
higher in PARP-2−/− mice, primarily esteriﬁed cholesterol showed
signiﬁcant accumulation, while hepatic phospholipid levels were left
unchanged (Fig. 1A–B). Next we veriﬁed whether hepatic cholesterol
overproduction leads to higher cholesterol levels elsewhere too,
but we did not observe higher cholesterol levels either in the faces
(Fig. 1C) or in the serum (Fig. 1D). To our surprise, further analysis re-
vealed that while LDL levels remained unchanged, HDL levels decreased
in the PARP-2−/− mice (Fig. 1E). We set out to analyze the molecular
background of increased hepatic cholesterol and lower HDL levels. To
that endwe created HepG2 cells in which PARP-2 was partially deleted.-2 mRNA (A) and protein (B) levels were determined in RT-qPCR reactions and Western
(scPARP-2) (n = 6/6). In panel B brightness and contrast were adjusted. (C) Cholesterol
and was determined in colorimetric assays as described in the Materials and methods.
roarray as described in the Materials andmethods. The result of the analysis was depicted
EBP target genes) were determined by RT-qPCR in the liver of PARP-2+/+ and PARP-2−/−
scPARP-2 HepG2 cells/PARP-2+/+ mice and ahPARP-2 HepG2 cells/PARP-2−/− mice at
µA
B
C
D
E
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Table 1
Functional grouping of dysregulated genes in scPARP-2 vs. shPARP-2 HepG2 cells.
Those genes are shown which had a change in expression of 1.5, or larger. *, ** and ***
indicate statistically signiﬁcant differences between scPARP-2 cells and shPARP-2 cells at
p b 0.05, p b 0.01 and p b 0.001, respectively.
Function Upregulated genes Downregulated genes
Name Fold Name Fold
Lipid homeostasis ACOX2 1.69×** ANXA1 −3.84×**
ANGPTL3 1.90×** OSBPL10 −1.62×**
APOM 1.75×** SERPINA3 −1.55×**
CYP7A1 2.37×**
CYP39A1 1.68×**
ELOVL2 1.59×***
FABP1 2.93×***
FADS2 1.59×***
LIPA 1.50×**
LIPG 1.67×**
MTTP 1.95×***
PCSK9 1.59×***
PPARGC1A 1.94×*
SULT2A1 1.52×**
TTPA 1.56×***
UGT2B4 1.74×***
Hepatic secretory functions CCL16 1.84×*** ADAM19 −2.69×***
CCL20 1.55×*** ANXA1 −3.84×**
CPB2 1.88×** CAPN2 −1.62×***
CPN1 2.02×** CPA4 −1.96×***
CSF3R 1.51×*** CPA6 −2.78×***
C1R 1.71×** CTSE −2.82×***
C1S 2.02×*** CD58 −1.53×**
C2 1.50×** DPEP1 −1.81×***
C5 1.85×*** FURIN −1.53×***
C8A 1.84×* IL8 −1.65×***
FGA 1.75×*** KLRC3 −1.56×**
FGG 1.69×** KLK6 −3.86×***
F13B 1.63×* MALT1 −1.55×***
HP 2.13×** MMP1 −1.56×***
HPR 2.04×*** NCF2 −1.74×**
IFIT5 1.64×** PLAT −1.75×*
IFITM3 1.53×*** PLAU −2.08×***
IL1RN 1.53×** PLAUR −1.59×***
KNG1 1.82×*** PRF1 −1.89×**
MASP1 1.54×*** PRSS23 −2.08×***
MASP2 1.59×*** QPCT −2.39×*
MBL2 1.56×*** SEMA3C −2.14×***
MEP1A 7.92×*** SERPINA3 −1.55×**
PCSK9 1.59×*** SERPINE1 −2.54×***
PRCP 1.54×** SERPINE2 −2.29×*
SERPINF2 1.59×*** SPP1 −1.59×**
SERPING1 2.15×*** TNFRSF9 −3.45×***
TNFSF10 2.06×*** TNFSF15 −1.68×**
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induces SREBP1-dependent genes
HepG2 cells were transduced with an shRNA construct directed
against PARP-2 (sh) or its scrambled (sc) control, giving rise to
shPARP-2 and scPARP-2 HepG2 cells, respectively. Transduction with
the speciﬁc shRNA reduced PARP-2 mRNA and protein expression to
50% (Fig. 2A–B). Furthermore, the depletion of PARP-2 induced the
cholesterol levels in the shPARP-2 HepG2 cells (Fig. 2C) similarly to
the situation in the liver of the PARP-2−/− mice. Next we compared
the steady state mRNA levels of the two cell lines in microarray ex-
periments. We have detected the dysregulation of 616 genes (change
in expression N+/−1.5), the majority of which were downregulated
in shPARP-2 HepG2 cells compared to scPARP-2 HepG2 cells (460
downvs. 156upregulated genes) (Fig. 2D, Supplementary Table 3.). Pre-
vious studies have already linked PARP-2 to transcription [5–7,15–18],
however such widespread effect on gene expression was unexpected.
We have observed altered expression in the following groups of genes:
hepatic secreted proteins (proteins involved in blood coagulation and
immune response), SIRT-1 regulated genes, lipid metabolism genes and
SREBP-dependent genes (Fig. 2D, Table 1).Higher expression of the SIRT1-dependent genes was in line with
our previous observations [5,14] that validated the current study.
The expression of genes involved in lipid metabolism increased in
the shPARP-2 cells (Fig. 2D). These genes encompass 1) lipid transport
(e.g. fatty acid binding protein-1 (FABP1), microsomal triglyceride
transfer protein (MTTP)); 2) lipid modiﬁcation (e.g. cytochrome P450,
family 7, subfamily A, polypeptide 1 (CYP7A1), cytochrome P450, family
39, subfamily A, polypeptide 1 (CYP39A1), fatty acid desaturase 2
(FADS2)) and 3) lipid breakdown (e.g. lipaseA (LIPA), endothelial lipase
(LIPG), acyl-CoA oxidase 2 (ACOX2)), which is in alignment with
decreased hepatic triglyceride storage and enhanced hepatic trigly-
ceride oxidation [5]. Furthermore, we have observed the induction of
genes involved in cholesterol biosynthesis: cytosolic 3-hydroxy-3-
methylglutaryl (HMG)-CoA synthase (HMGCS1), HMG-CoA reductase
(HMGCR), LDL receptor (LDLR), farnesyl diphosphate synthase (FDPS),
cytochrome P450, family 51 subfamily A, polypeptide 1 (cyp51A1),
stearoyl-CoA delta-9-desaturase (SCD), cetyl-CoA carboxylase alpha
(ACACA), fatty acid synthase (FASN), ATP citrate lyase (ACLY), PPARG,
and malic enzyme 2 (ME2). In line with these ﬁndings HMGCS1 and
HMGCR were induced in the livers of PARP-2−/−mice (Fig. 2E).
Higher cholesterol levels and the induction of genes of cholesterol
synthesis suggested that the knockdown of PARP-2 directly affected
transcription factor(s). It was likely that sterol regulatory element-
binding proteins (SREBPs), SREBP1 and -2, both responsible for the
cholesterol biosynthesis and cholesterol import [19,20], mediated the
effect of PARP-2 knockdown on sterol biosynthesis. Upon activation,
membrane-bound SREBPs undergo a cascade of proteolytic cleavage
leading to their nuclear translocation and transcriptional activation
[21,22]. Processed SREBP1 and -2 bind to speciﬁc promoters and, in
turn, enhance the transcription of genes involved in cholesterol biosyn-
thesis and transport, such as HMGCS, HMGCR, LDLR, FDPS, cytochrome
P450, cyp51A1, SCD, ACACA, FASN, ACLY, PPARG and ME2 [21–23]. Our
observation that these genes were induced in shPARP-2 HepG2 cells
points towards enhanced transactivation by SREBPs.
The induction of SREBP-mediated genes upon the partial deletion of
PARP-2 suggested the involvement of SREBP1 and/or SREBP2. Therefore
we analyzed the expression of SREBP1 and SREBP2 in scPARP2 and
shPARP2 HepG2 cells. We have observed higher expression of SREBP1,
but not of SREBP2 in shPARP-2 HepG2 cells (Fig. 3A). In line with
these ﬁndings, SREBP1 mRNA expression was higher in PARP-2−/−
mice than in PARP-2+/+ mice (Fig. 3B). Higher SREBP1 mRNA levels
were translated into increased protein levels both in cells and in mice
(Figs. 3C, D, S1A, C). We also analyzed the protein expression of two
SREBP-dependent genes, HMGCS1 and HMGCR that were induced in
both models (Figs. 3C, D, S1B, D).
SREBP1 localization was characterized in HepG2 cells by cell frac-
tionation followed by Western blotting and by confocal microscopy.
The full length (unprocessed, cytoplasmic) and cleaved (processed,
nuclear) form of SREBP1 protein was higher in shPARP-2 HepG2 cells
as shown in cell fractionation experiments (Figs. 3C, S1A). Conforming
with these ﬁndings, the protein level of the processed form of SREBP1,
HMGCS1 and HMGCR was higher in total protein extracts from PARP-
2−/− mice than in extracts from PARP-2+/+ mice (Figs. 3D, S1C).
Confocal microscopy – performed on scPARP-2 and shPARP-2 HepG2
cells – not only conﬁrmed the above ﬁndings, but also revealed that
SREBP1 content in the nuclear compartment was higher as compared
to the cytoplasm in shPARP-2 HepG2 cells (Fig. 3E). Apparently the par-
tial deletion of PARP-2 induces SREBP1 expression and nuclear trans-
location suggesting higher SREBP1-mediated transactivation that is
translated into higher expression of the genes of cholesterol biosynthe-
sis that likely explains higher cholesterol levels observed in the shPARP-
2 HepG2 cells. We did not detect changes in SREBP2 protein levels
and localization (data not shown) therefore we omitted it from further
investigation.
Higher SREBP1 expression suggests that PARP-2 probably mediates
the activity of the promoter of SREBP1. Indeed, the depletion of PARP-
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Fig. 3. PARP-2 knockdown induces the expression and nuclear accumulation of SREBP1. (A) SREBP1 and -2mRNA levelswere determined in RT-qPCR reactions in scPARP-2 and shPARP-2
HepG2 cells (n = 3/3). (B) mRNA levels of SREBP1 were determined by RT-qPCR in the liver of PARP-2+/+ and PARP-2−/−mice (n = 7/6, age 6 months). (C) scPARP-2 and shPARP-2
HepG2 cells were fractionated (n = 3/3) as described in theMaterials andmethods. Nuclear and cytosolic fractions were analyzed for SREBP1 content byWestern blotting. Furthermore,
from the cytosolic fraction HMGCS1 and HMGCRwere also determined byWestern blotting. The results of densitometric analysis are in Fig. S1A–B. (D) Protein levels of SREBP1, HMGCS1
and HMGCR were determined by Western blotting in the liver of PARP-2+/+ and PARP-2−/− mice (n = 7/6, age 6 months). The results of densitometric analysis are in Fig. S1C–D.
(E) Cellular localization of SREBP1was detectedusing immunoﬂuorescence staining followed by confocalmicroscopy in sc PARP-2 and shPARP-2HepG2 cells, as described in theMaterials
and methods. Scale bar equals 2 μm. * and ** indicate statistically signiﬁcant differences between scPARP-2 HepG2 cells/PARP-2+/+ mice and ahPARP-2 HepG2 cells/PARP-2−/−mice
at p b 0.05 and p b 0.01, respectively. In panel B error is given as SEM.
599M. Szántó et al. / Biochimica et Biophysica Acta 1842 (2014) 594–6022 induced the activity of the promoter of SREBP1 as shown in luciferase
reporter assays (Fig. 4A) suggesting that PARP-2 is a repressor of
the SREBP1 promoter. Previously it has been shown for numerous
promoters that PARP-2 exerts its activity by directly binding to DNA
[5,6,14,15,17] that seems likely in the case of the SREBP1 promoter,
too. To verify, we performed ChIP assays using an antibody against
PARP-2 and oligonucleotide probes for SREBP1 (speciﬁc probes for
the SREBP1 promoter and SREBP1 coding region) and keratin 19 (K19)
promoter (non-PARP-2 dependent promoter, a negative control [6]).
In these ChIP assays we found the following:
1) PARP-2 is more abundant on the SREBP1 promoter in the scPARP-2
than in the shPARP-2 HepG2 cells reﬂecting the actual expression
levels of PARP-2 (measurements with the anti-PARP-2 antibody
and the SREBP1 promoter probe comparing both cell lines; Fig. 4B
comparing the ﬁrst two bars)
2) In both cell lines the negative controls of the anti-PARP-2 antibody
(nonspeciﬁc antibody and the no antibody control) displayed lower
signals than the speciﬁc anti-PARP-2 antibody (Fig. 4B comparing
the black bars).
3) The signal of the anti-PARP-2 antibody was lower on the non-
speciﬁc K19 promoter than on the SREBP1 promoter in scPARP-2
HepG2 cells (Fig. 4B–C comparing black bars on both charts).
4) We did not obtain any signal from the coding region of SREBP1
(signal of the anti-PARP-2 antibody using a probe against the
SREBP1 coding region; data not shown).
In conclusion, reduced signal of the anti-PARP-2 antibody in
shPARP-2 HepG2 cells (detailed above) as compared to the signal in
scHepG2 cells from the SREBP1 promoter suggests that the signal ofthe anti-PARP-2 antibody is speciﬁc and PARP-2 indeed binds to the
promoter of SREBP1. It is very likely therefore that the presence of
PARP-2 on the SREBP1 promoter suppresses SREBP1 expression by
directly binding to the promoter of the SREBP1 gene.
We assessed whether the enzymatic activity of PARP-2 plays role in
the regulation of the expression of SREBP1. To that end we treated
scPARP-2 and shPARP-2 HepG2 cells with UPF1069, a PARP inhibitor
that shows preference towards PARP-2 as compared to PARP-1 and
was shown tomimic the action of PARP-2 ablation [24]. Cellswere treat-
ed with UPF1069 for 24 h without detectable changes in total cellular
PARP activity (data not shown). In other words, UPF1069 treatment
affected the activity of PARP-2 but not the activity of PARP-1, as PARP-
2 represents 10–15% of total cellular PARP activity [2,5,14,25]. We
then analyzed the expression of SREBP1 and a selection of SREBP1-
mediated genes (HMGCS1, HMGCR, SCD, PPARG and FPDS) in vehicle/
UPF1069-treated sc/shPARP-2 HepG2 cells. The treatment of scPARP-2
HepG2 cells resulted in the enhanced expression of SREBP1 and the
aforementioned SREBP1-dependent genes (Fig. 4D) suggesting that
the enzymatic activity of PARP-2 is important in mediating SREBP1-
dependent gene expression. Furthermore, UPF1069did not cause signif-
icant induction of SREBP1 and SREBP1-mediated genes verifying our
ﬁndings (Fig. 4D) in shPARP-2 HepG2 cells.
3.3. Lower HDL levels in PARP-2−/−mice are due to the reduced expression
of ABCA1
The initial phenotyping of the liver of PARP-2−/− mice revealed
lower HDL levels (Fig. 1E). Previous studies have linked lower
HDL levels to the downregulation of adenosine triphosphate-binding
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analyzed mRNA and protein levels of ABCA1 in HepG2 cells and
in mice. ABCA1 mRNA and protein levels decreased upon the deletion
of PARP-2 in HepG2 cells (Figs. 5A, S2A) and in mice (Figs. 5B, S2B).0
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In the present study we have extended the role of PARP-2 in lipid
metabolism showing that PARP-2 impacts on cholesterol homeostasis.
The deletion of PARP-2 induced cholesterol levels in the liver and
decreased serum HDL levels. To identify the underlying molecular
mechanism we performed microarray studies, whereby we revealed
the dysregulation of 616 genes, although fold changes in expression
levels were limited (roughly around +/−2–2.5 fold). Previous studies
have linked PARP-2 to transcriptional regulation [5–7,14–18,28,29].
Moreover, a recent study showed differences in gene expression be-
tween bone marrow cells of PARP-2+/+ and PARP-2−/− mice upon
gamma irradiation [29]. However, such widespread rearrangement of
gene expression in unchallenged cells upon the depletion of PARP-2
was unexpected. We have identiﬁed new groups of genes linked to
the expressionof PARP-2 (hepatic secretory activity and cholesterol bio-
synthesis) in addition to the previously known groups (SIRT1-regulated
genes, lipid metabolism genes, cell death genes and surfactant protein
B) [5–7,15–18].
PARP-2 associateswith numerous transcription factors, among them
nuclear receptors [e.g. estrogen receptor (ER)α and PPARs] as reviewed
in [4]. Not surprisingly, studies have already linked PARP-2 to epigenetic
regulation that is a likely mode of action for PARP-2 in the regulation of
gene expression. Quenet et al. [30] have shown that PARP-2 interacts
with tripartite motif containing 28 (TIF1β) and heterochromatin pro-
tein (HP)1α inducing condensation to heterochromatin. Furthermore,
Liang et al. [17] recently found that the presence of PARP-2 enhances
the recruitment of histone deacetylase (HDAC)5 and HDAC7 and the
histone methyltransferase G9a to promoters. In the same study Liang
et al. [17] reported that the suppression of gene expression exerted by
PARP-2was independent of the enzymatic activation of PARP-2. Hereby,
we have shown that the inhibition of PARP-2 by UPF1069 had similar
effect as the knockdown of PARP-2 suggesting that – at least for
SREBP1 – the enzymatic activity of PARP-2 is crucial for the suppression
of the promoter. What causes the discrepancy between these studies?
Liang et al. [17] utilized genetic tools to assess the activity of PARP-2,
while we applied pharmacological means. On the one hand UPF1069
is not a highly speciﬁc PARP-2 inhibitor (it shows 60-fold preference
towards PARP-2, as compared to PARP-1 in vitro), therefore it cannot
be excluded that UPF1069 may inhibit other PARP enzymes as well
[24,31]. Another explanation is that PARP-2 inhibits certain promoters
in a poly(ADP-ribose)-dependent, while others in a poly(ADP-ribose)-
independent way. At that point it's impossible to make a deﬁnitive
selection between these explanations. However, it is important to note
that the activity-dependent regulation of gene expression may provide
means for pharmacological intervention.
These data provide a likely explanation for the upregulation of cer-
tain genes upon the knockdown of PARP-2 (~25% of all dysregulated
genes), but does not explain the molecular mechanism through which
the majority of genes (~75%) are downregulated under the same
condition. It is likely that PARP-2 could act through similar molecular
mechanisms as PARP-1 (see [32,33]) to mediate gene expression.
Therefore, by analogy with PARP-1, in the future it might be possible
to explain how PARP-2 can act as a positive transcriptional cofactor.
By analyzing changes in the expression of the lipid metabolism
genes, we found that PARP-2 is a suppressor of the SREBP1 promoter.
The knockdown of PARP-2 therefore probably induces SREBP1 expres-
sion that leads to cholesterol synthesis and import culminating in choles-
terol accumulation. Our data, therefore, identify PARP-2 as a suppressor
of SREBP1 expression, similarly to early growth response protein-1
(EGR-1) or FOXO1 [34,35].
Excess hepatic cholesterol was expected to be exported from the
liver leading to elevated serum and fecal cholesterol or LDL levels, but
this could not be observed. Moreover, to our surprise, serum HDL levels
were signiﬁcantly reduced in the PARP-2−/− mice. This unexpected
ﬁnding is likely explained by the decreased expression of ABCA1transport protein that is essential in transferring cholesterol to apolipo-
protein A1 in the liver and the intestine [26,27,36]. Defect in ABCA1
function manifests in humans as the Tangier disease, that is character-
ized by decrease in HDL levels and higher risk for atherosclerosis and
its sequalae [26,27,37,38]. Therefore lower ABCA1 expression seems to
explain decreased HDL levels in PARP-2−/−mice. The actual molecular
mechanism through which the deletion of PARP-2 leads to lower
expression of ABCA1 remains to be explored, althoughwe have excluded
the direct action of PARP-2 on the promoter of ABCA1.
Apparently PARP-2 has widespread effects on lipid homeostasis.
Upon the depletion of PARP-2 triglyceride storage is reduced in the
WAT and liver [5,6], while triglyceride oxidation is enhanced in skeletal
muscle and liver [5]. Here we show that the depletion of PARP-2
enhances hepatic cholesterol synthesis and decreases HDL synthesis.
As a result, serum free fatty acid, triglyceride and HDL levels are
reduced, while LDL levels do not change in PARP-2−/−mice. Low HDL
levels represent a risk factor to several cardiovascular diseases [39,40].
Interestingly, the depletion of anothermember of the PARP superfamily,
PARP-1 protects from several cardiovascular diseases [41–46]. It might
be possible that PARP-1 and PARP-2 have different and, at some points,
opposing effects in predisposing to cardiovascular diseases that may
necessitate further research efforts in that direction.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2013.12.006.
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